Skip to main content

CITADEL ADVISORS LLC

Position in GRCE — Grace Therapeutics, Inc.

CIK 1423053 MIAMI, FL

Position in GRCE

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$793,909
+$336,735 QoQ
Shares Held
349,740
+254.2% QoQ
Ownership
1.66%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#5
of 33 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in GRCE Over Time

Shares Held

Position Value (USD)

Derivatives in GRCE

reported options exposure · as of Jun 30, 2026
CallValue
$119,175
CallShares
52,500
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CITADEL ADVISORS LLC holds $6,088,855,369 across 436 Biotechnology names. GRCE ranks #247 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in GRCE

Export CSV
8 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $793,909 349,740
2026-06-30 $119,175 52,500
2026-03-31 $457,174 98,742
2025-12-31 $146,347 42,297
2025-09-30 $81,249 27,265
2025-06-30 $102,114 34,382
2025-03-31 $87,558 38,403
2024-12-31 $88,503 23,664